JN. Chu et al., 2018.
Immune checkpoint inhibitors such as anti-CTLA4 and anti-PD1 antibodies represent a paradigm shift in the treatment of many advanced malignancies. However, immune related adverse effects (irAEs) result in increasing inpatient admissions and the cost burden related to irAEs is unknown. We describe the cost of admissions for irAEs to a tertiary academic center.
Chu, J. N., Choi, J. G., Ostvar, S., Cohen, J. V., Allen, I. M., Dougan, M. L., Villani, A. C., Thomas, M., Nasrallah, M., Guidon, A., Chen, S. T., Schoenfeld, S., Sise, M., Leaf, R., Neilan, T. G., Faje, A., Sullivan, R. J., Bardia, A., Hur, C., & Reynolds, K. L. (2018). Cost of inpatient admissions for immune-related adverse effects from immune checkpoint inhibitor therapy: A single center experience. Journal of Clinical Orthodontics: JCO, 36(15_suppl), 3060–3060.
Comments